CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) – Pipeline Review, H2 2016’, provides in depth analysis on CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted pipeline therapeutics.

The report provides comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)

The report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects

The report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Biogen Inc

Bristol-Myers Squibb Company

eTheRNA Immunotherapies NV

ImmuNext, Inc.

Juno Therapeutics Inc.

MedImmune, LLC

Mologen AG

Targovax ASA

XL-protein GmbH

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Overview 8

Therapeutics Development 9

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Products under Development by Stage of Development 9

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Products under Development by Therapy Area 10

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Products under Development by Indication 11

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Products under Development by Companies 15

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Products under Development by Universities/Institutes 18

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Companies Involved in Therapeutics Development 27

Biogen Inc 27

Bristol-Myers Squibb Company 28

eTheRNA Immunotherapies NV 29

ImmuNext, Inc. 30

Juno Therapeutics Inc. 31

MedImmune, LLC 32

Mologen AG 33

Targovax ASA 34

XL-protein GmbH 35

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drug Profiles 36

Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

BIIB-063 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

BMS-986004 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Delta-24-RGDOX - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

hepatitis B vaccine - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ISF-35 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

LOAd-700 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

MEDI-4920 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

MegaCD40L - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

MGN-1601 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Oligonucleotide to Activate CD40L, CD70 and TLR-4 for Oncology and Infectious Diseases - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

ONCOS-402 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

PG-10203 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

TDI-28 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

TDI-846 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

UltraCD40L - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

XL-050 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Dormant Projects 60

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Featured News & Press Releases 62

Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with Checkpoint Inhibitors in a Model of Metastatic Melanoma 62

Sep 16, 2015: MOLOGEN is presenting poster on MGN1601 at International Cancer Immunotherapy Conference 62

Sep 18, 2014: MOLOGEN Presents Poster Presentations of MGN1601 at ESMO 2014 Congress 63

May 07, 2014: MOLOGEN: Immunological data on renal cancer therapy MGN1601 presented at CIMT 63

Feb 03, 2014: MOLOGEN: Final results from renal cancer trial with MGN1601 presented at ASCO Genitourinary Cancers Symposium 64

Oct 01, 2012: Mologen Presents Updated Data On Renal Cancer Therapy MGN1601 At European Society For Medical Oncology 2012 65

Mar 30, 2012: MOLOGEN Announces Treatment With Renal Cancer Therapy MGN1601 Generates Clear Survival Benefit For Patients 65

Feb 21, 2012: MOLOGEN Wins Patent Protection In Japan For Cell-Based Cancer Therapy MGN1601 67

Dec 07, 2011: Memgen Announces Upcoming Presentation For ISF35 In Chronic Lymphocytic Leukemia At 2011 ASH Annual Meeting 67

Nov 21, 2011: MOLOGEN Attains Goals Of Renal Cancer Study With MGN1601 Ahead Of Schedule 68

Nov 21, 2011: MOLOGEN Attains Goals Of Renal Cancer Study With MGN1601 Ahead Of Schedule 69

Aug 29, 2011: MOLOGEN Publishes First Results From Phase I/II Clinical Trial With Cell-Based Renal Cancer Therapy MGN1601 70

Aug 29, 2011: MOLOGEN Publishes Results From Phase I/II Clinical Trial Of Renal Cancer Therapy 71

Jun 21, 2011: Memgen Presents Clinical Results For ISF35 In Chronic Lymphocytic Leukemia At ASCO 2011 71

Feb 23, 2011: MOLOGEN To Receive Europen Patent For Allogenic Tumor Therapy 72

Appendix 73

Methodology 73

Coverage 73

Secondary Research 73

Primary Research 73

Expert Panel Validation 73

Contact Us 73

Disclaimer 74

List of Tables

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

Pipeline by Biogen Inc, H2 2016 27

Pipeline by Bristol-Myers Squibb Company, H2 2016 28

Pipeline by eTheRNA Immunotherapies NV, H2 2016 29

Pipeline by ImmuNext, Inc., H2 2016 30

Pipeline by Juno Therapeutics Inc., H2 2016 31

Pipeline by MedImmune, LLC, H2 2016 32

Pipeline by Mologen AG, H2 2016 33

Pipeline by Targovax ASA, H2 2016 34

Pipeline by XL-protein GmbH, H2 2016 35

Dormant Projects, H2 2016 60

Dormant Projects (Contd..1), H2 2016 61

List of Figures

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Top 10 Indication, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 21

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Molecule Types, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 25

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports